Literature DB >> 12872365

Reduced bikunin gene expression as a factor of poor prognosis in ovarian carcinoma.

Yoshiko Tanaka1, Hiroshi Kobayashi, Mika Suzuki, Naohiro Kanayama, Mitsuaki Suzuki, Toru Yamakawa, Hideaki Morishita, Toshihiko Terao.   

Abstract

BACKGROUND: In previous studies, the authors showed that various types of cultured tumor cells treated with exogenous bikunin protein or ovarian carcinoma cells transfected with bikunin cDNA have low invasiveness and diminished metastatic potential. This study was carried out to clarify the relation between the expression of individual bikunin mRNA and tumor progression.
METHODS: Forty-one newly diagnosed ovarian carcinomas were investigated using a semiquantitative reverse transcriptase-polymerase chain reaction.
RESULTS: The authors found that 24 patients had tumors that overexpressed bikunin and that gene expression was reduced in the tumors of the remaining 17 individuals. Bikunin mRNA expression was independent of age, surgical stage, tumor size, degree of differentiation, histologic subtype, and serum CA 125 levels. There was a significant correlation between low expression of bikunin mRNA and lymph node status (P=0.035) or peritoneal status (P=0.042). Multivariate analysis indicated that bikunin was an independent prognostic marker (P=0.013; hazard ratio, 2.30; 95 % confidence interval, 1.13-4.19), even after controlling for lymph node metastasis and the degree of peritoneal dissemination. In addition, low expression was a significant predictor for poor prognosis compared with high expression (2-year survival rate; 75.0 % vs. 47.1 %, respectively; P<0.05).
CONCLUSIONS: The data suggest that low bikunin mRNA expression by ovarian carcinoma cells may be associated with poor prognosis. It is conceivable that testing for bikunin mRNA may identify patients with ovarian carcinoma who are at high risk for early disease recurrence and a poor prognosis. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12872365     DOI: 10.1002/cncr.11506

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Transcriptome analysis of human gastric cancer.

Authors:  Jung-Hwa Oh; Jin Ok Yang; Yoonsoo Hahn; Mi-Rang Kim; Sang-Soon Byun; Yeo-Jin Jeon; Jeong-Min Kim; Kyu-Sang Song; Seung-Moo Noh; Sangsoo Kim; Hyang-Sook Yoo; Yong Sung Kim; Nam-Soon Kim
Journal:  Mamm Genome       Date:  2005-12-08       Impact factor: 2.957

Review 2.  The Inter-α-Trypsin Inhibitor Family: Versatile Molecules in Biology and Pathology.

Authors:  Megan S Lord; James Melrose; Anthony J Day; John M Whitelock
Journal:  J Histochem Cytochem       Date:  2020-07-08       Impact factor: 2.479

Review 3.  Ovarian cancer biomarkers: current options and future promise.

Authors:  Christine M Coticchia; Jiang Yang; Marsha A Moses
Journal:  J Natl Compr Canc Netw       Date:  2008-09       Impact factor: 11.908

Review 4.  New Predictive Biomarkers for Ovarian Cancer.

Authors:  Ghofraan Abdulsalam Atallah; Nor Haslinda Abd Aziz; Chew Kah Teik; Mohamad Nasir Shafiee; Nirmala Chandralega Kampan
Journal:  Diagnostics (Basel)       Date:  2021-03-07

5.  beta(2)microglobulin mRNA expression levels are prognostic for lymph node metastasis in colorectal cancer patients.

Authors:  J Shrout; M Yousefzadeh; A Dodd; K Kirven; C Blum; A Graham; K Benjamin; R Hoda; M Krishna; M Romano; M Wallace; E Garrett-Mayer; M Mitas
Journal:  Br J Cancer       Date:  2008-05-27       Impact factor: 7.640

6.  Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival.

Authors:  Athanasios Karapetsas; Antonis Giannakakis; Denarda Dangaj; Evripidis Lanitis; Spyridon Kynigopoulos; Maria Lambropoulou; Janos L Tanyi; Alex Galanis; Stylianos Kakolyris; Gregorios Trypsianis; George Coukos; Raphael Sandaltzopoulos
Journal:  Biomed Res Int       Date:  2015-09-13       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.